(Q39251898)

10 September 2017

title

RSK promotes G2 DNA damage checkpoint silencing and participates in melanoma chemoresistance (English)

1 reference

10 September 2017

0 references

7

1 reference

10 September 2017

H Ray-David

1

1 reference

10 September 2017

Y Romeo

2

1 reference

10 September 2017

G Lavoie

3

1 reference

10 September 2017

P Déléris

4

1 reference

10 September 2017

J Tcherkezian

5

1 reference

10 September 2017

J A Galan

6

1 reference

10 September 2017

language of work or name

English

0 references

publication date

29 October 2012

1 reference

10 September 2017

1 reference

10 September 2017

volume

32

1 reference

10 September 2017

issue

38

1 reference

10 September 2017

page(s)

4480-4489

1 reference

https://scigraph.springernature.com/pub.10.1038/onc.2012.472

10 September 2017

exact match

0 references

cites work

The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.472

The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.472

The ERK cascade: a prototype of MAPK signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.472

Hyperactive Ras in developmental disorders and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.472

BRAF(E600) in benign and malignant human tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.472

New insight into BRAF mutations in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.472

Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.472

Regulation and function of the RSK family of protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.472

Attenuation of proteasome-induced proteolysis in skeletal muscle by {beta}-hydroxy-{beta}-methylbutyrate in cancer-induced muscle loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.472

Structural bioinformatics-based design of selective, irreversible kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.472

Paving the way for targeting RSK in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.472

Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.472

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.472

The MAPK pathway in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.472

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.472

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.472

BRAF mutation predicts sensitivity to MEK inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.472

Malignant melanoma in the 21st century, part 2: staging, prognosis, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.472

Chemotherapy and targeted therapy combinations in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.472

Chemotherapy for metastatic melanoma: time for a change?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.472

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.472

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.472

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.472

Molecular mechanisms of cisplatin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.472

Chk1 C-terminal regulatory phosphorylation mediates checkpoint activation by de-repression of Chk1 catalytic activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.472

Specific role of Chk1 phosphorylations in cell survival and checkpoint activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.472

A role for PI 3-kinase and PKB activity in the G2/M phase of the cell cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.472

P90 RSK arranges Chk1 in the nucleus for monitoring of genomic integrity during cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.472

Lack of PTEN sequesters CHK1 and initiates genetic instability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.472

BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.472

The selectivity of protein kinase inhibitors: a further update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.472

Oncogenic MAPK signaling stimulates mTORC1 activity by promoting RSK-mediated raptor phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.472

Phosphorylation of p90 ribosomal S6 kinase (RSK) regulates extracellular signal-regulated kinase docking and RSK activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.472

RAS oncogenes: the first 30 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.472

Polo-like kinases: a team in control of the division

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.472

Polo-like kinase-1 controls proteasome-dependent degradation of Claspin during checkpoint recovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.472

SCFbetaTrCP-mediated degradation of Claspin regulates recovery from the DNA replication checkpoint response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.472

The substrates of Plk1, beyond the functions in mitosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.472

Melanoma biology and new targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.472

Apoptosis and melanoma chemoresistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.472

Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.472

RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.472

mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.472

The serine/threonine protein kinase, p90 ribosomal S6 kinase, is an important regulator of prostate cancer cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.472

Prognostic factors for survival of patients treated systemically for disseminated melanoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.472

A comprehensive map of the mTOR signaling network

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.472

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/ONC.2012.472

1 reference

10 September 2017

1 reference